Vanda Pharmaceuticals Inc. (FRA:VM4)
Germany · Delayed Price · Currency is EUR | Market Cap | 372.40M |
| Revenue (ttm) | 180.75M |
| Net Income (ttm) | -71.76M |
| Shares Out | n/a |
| EPS (ttm) | -1.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 349 |
| Open | 7.15 |
| Previous Close | 6.80 |
| Day's Range | 7.15 - 7.15 |
| 52-Week Range | 3.46 - 7.60 |
| Beta | n/a |
| RSI | 55.08 |
| Earnings Date | Feb 12, 2026 |
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) ... [Read more]
News
FDA Approves Vanda Pharma Motion Sickness Drug, Fuels Upside
In December, the U.S. Food and Drug Administration (FDA) approved Vanda Pharmaceuticals Inc. ‘s (NASDAQ: VNDA) Nereus (tradipitant) to prevent vomiting induced by motion . The approval marks the firs...
Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn't (Rating Downgrade)
Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus
Vanda Pharmaceuticals is buy-rated following FDA approval of Nereus for motion sickness, with shares offering upside into 2026 catalysts. VNDA's Q3 saw strong Fanapt sales growth, but higher R&D and S...
What's Going On With Vanda Pharmaceuticals Stock Wednesday?
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares are trading higher Wednesday after the company announced it received FDA approval of NEREUS for the prevention of vomiting induced by motion . Vanda P...
Vanda Pharmaceuticals Stock Surges 29% After FDA Clears Motion Sickness Drug
(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) shares jumped 29.13%, trading at $9.08, up $2.05, after the company announced that the U.S. Food and Drug Administration approved NEREUS (tradipitant) for...
Why FuelCell Energy Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of FuelCell Energy, Inc. (NASDAQ: FCEL) fell sharply during Wednesday's session after the company filed for an amended common stock offering . After market close on Tuesday, FuelCell said in a...
Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval
The FDA approved Vanda's drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked to GLP-1 weight-loss drugs.
Vanda Pharmaceuticals (VNDA) Surges 21% on FDA Approval of Motion Sickness Drug
Vanda Pharmaceuticals (VNDA) Surges 21% on FDA Approval of Motion Sickness Drug
Vanda Pharmaceuticals (VNDA) Gains FDA Nod for Motion Sickness Drug
Vanda Pharmaceuticals (VNDA) Gains FDA Nod for Motion Sickness Drug
Vanda surges on FDA approval of Lilly-partnered motion sickness therapy
Vanda Pharmaceuticals (VNDA) stock rises as the FDA approves its motion sickness therapy Nereus, developed in partnership with Eli Lilly (LLY). Read more here.
Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Shares of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) rose sharply in pre-market after the company announced U.S. Food and Drug Administration approval of NEREUS (tradipitant), an oral neurokinin-1 rec...
Vanda Pharmaceuticals (VNDA) Surges on FDA Approval
Vanda Pharmaceuticals (VNDA) Surges on FDA Approval
FDA Greenlights Vanda Pharmaceuticals' (VNDA) New Motion Sickness Drug
FDA Greenlights Vanda Pharmaceuticals' (VNDA) New Motion Sickness Drug
Vanda Pharmaceuticals (VNDA) Shares Surge Following FDA Approval
Vanda Pharmaceuticals (VNDA) Shares Surge Following FDA Approval
Biggest stock movers Wednesday: Vanda Pharmaceuticals and Cybin
Vanda Pharmaceuticals, One Stop Systems And 3 Stocks To Watch Heading Into Wednesday
With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Oriental Rise Holdings Ltd. (NASDAQ: ORIS) announced a nonbindin...
Why Is Vanda Pharmaceuticals' (VNDA) Stock Trending Overnight?
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares are trending on Wednesday. Check out the current price of VNDA stock here . Shares of the biopharmaceutical company jumped 20.20% to $8.45 in after-ho...
FDA Approves Vanda's NEREUS For Motion Sickness; Shares Jump Over 20% In Overnight Trading
(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the pre...
US FDA approves Vanda Pharmaceuticals' motion sickness drug
Vanda Pharmaceuticals said on Tuesday its drug for the prevention of motion-induced vomiting was approved by the U.S. health regulator, becoming the first treatment for the condition to receive the no...
Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces FDA Approval of NEREUS (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
WASHINGTON, Dec. 30, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS (tradipitant), an o...
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
WASHINGTON, Dec. 30, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™ (tradipitant), an oral...
Vanda Pharmaceuticals (VNDA) Submits BLA to FDA for New Psoriasis Treatment
Vanda Pharmaceuticals (VNDA) Submits BLA to FDA for New Psoriasis Treatment
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
WASHINGTON , Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administr...
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
WASHINGTON , Dec. 11, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco...
FDA Removes Partial Clinical Hold On Tradipitant For Motion Sickness
(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) announced on Thursday that the U.S. FDA has lifted the partial clinical hold on its motion sickness protocol, VP-VLY-686-3403, for Tradipitant, which had ...